More than a month after the launch of the new iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program, the operation still isn't running smoothly for many dermatologists, pharmacists, and ...
In December 2021, major changes took effect in the iPLEDGE program, the US Food and Drug Administration (FDA)–required safety program for managing the risks of isotretinoin's teratogenicity and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results